

AMENDMENT

Please amend the application without prejudice, without admission, without surrender of subject matter, and without any intention of creating any estoppel as to equivalents as follows.

IN THE CLAIMS

1-22. (Canceled)

23. (New) A transgenic model mouse for interstitial pneumonia or inflammatory bowel disease which is obtained by introducing an OX40L expression vector, having an OX40L gene integrated therein at downstream of the T-cell specific lck promoter, into a mouse fertilized egg and by backcrossing the mouse with a C57BL/6 line mouse, which constantly expresses OX40L in T cells, and which has a spontaneous onset of interstitial pneumonia and inflammatory bowel disease.

24. (New) The transgenic model mouse for interstitial pneumonia or inflammatory bowel disease according to claim 23, wherein the OX40L gene is comprised of SEQ ID NO: 1.

25. (New) The transgenic model mouse for interstitial pneumonia or inflammatory bowel disease according to claim 23, wherein the inflammatory bowel disease has an onset of moderate to severe hyperplasia of lymphatic system in the intestinal basal membrane, hyperplasia of mucous epithelium in basal membrane, lymphocyte invasion or hyperplasia of submucous lymphoid follicle.

26. (New) The transgenic model mouse for interstitial pneumonia or inflammatory bowel disease according to claim 24, wherein the inflammatory bowel disease has an onset of moderate to severe hyperplasia of lymphatic system in the intestinal basal membrane, hyperplasia of mucous epithelium in basal membrane, lymphocyte invasion or hyperplasia of submucous lymphoid follicle.

27. (New) The transgenic model mouse for interstitial pneumonia or inflammatory bowel disease according to claim 23, wherein the backcrossing is conducted at least for 12 generations.

28. (New) The transgenic model mouse for interstitial pneumonia or inflammatory bowel disease according to claim 24, wherein the backcrossing is conducted at least for 12 generations.

29. (New) The transgenic model mouse for interstitial pneumonia or inflammatory bowel disease according to claim 25, wherein the backcrossing is conducted at least for 12 generations.

30. (New) The transgenic model mouse for interstitial pneumonia or inflammatory bowel disease according to claim 26, wherein the backcrossing is conducted at least for 12 generations.

31. (New) A method for constructing of a transgenic mouse as a model animal for interstitial pneumonia or inflammatory bowel disease, wherein the transgenic mouse is obtained by introducing an OX40L expression vector, having an OX40L gene integrated therein at downstream of the T-cell specific lck promoter, into a mouse fertilized egg and by backcrossing the mouse with a C57BL/6 line mouse and which constantly expresses OX40L in T cells and which has a spontaneous onset of interstitial pneumonia and inflammatory bowel disease.

32. (New) The method of use according to claim 31, wherein the OX40L gene is comprised of SEQ ID NO: 1.

33. (New) The method according to claim 31, wherein the inflammatory bowel disease has an onset of moderate to severe hyperplasia of lymphatic system in the intestinal basal membrane, hyperplasia of mucous epithelium in basal membrane, lymphocyte invasion or hyperplasia of submucous lymphoid follicle.

34. (New) The method according to claim 32, wherein the inflammatory bowel disease has an onset of moderate to severe hyperplasia of lymphatic system in the intestinal basal membrane, hyperplasia of mucous epithelium in basal membrane, lymphocyte invasion or hyperplasia of submucous lymphoid follicle.

35. (New) The method according to claim 31, wherein the backcrossing is conducted at least for 12 generations.

36. (New) The method according to claim 32, wherein the backcrossing is conducted at least for 12 generations.

37. (New) The method according to claim 33, wherein the backcrossing is conducted at least for 12 generations.

38. (New) The method according to claim 34, wherein the backcrossing is conducted at least for 12 generations.